Pfizer units settle with DOJ for $34.7M
World drug giant Pfizer says that two subsidiaries of Pharmacia, the firm it acquired in March 2003, have agreed to pay $34.7 million in fines to settle litigation with the US Department of Justice.
One unit, Pharmacia & Upjohn, will plead guilty to a single count of offering to an outside vendor remuneration in the form of an award of a contract to manage a patient assistance program for its human growth hormone Genotropin as an inducement for recommending Pharmacia drugs. The contract was awarded in 2000.
The subsidiary, which Pfizer stressed has no operational role in the firm, was assessed a fine of $19.7 million and will be disqualified from participating in government health care programs. The move will have no impact on current or future Pfizer medicines approved for use in the USA and will not affect the continued marketing of Genotropin, the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze